Targets › NFE2L2
4 programs from 4 companies in 6 trials: 3 Phase 2, 2 Phase 3, 1 Phase 1; Neurology, Metabolic and endocrine, Oncology; next expected readout Oct 2027.
Transcription factor that plays a key role in the response to oxidative stress: binds to antioxidant response (ARE) elements present in the promoter region of many cytoprotective genes, such as phase 2 detoxifying enzymes, and promotes their expression, thereby neutralizing reactive electrophiles. In normal conditions, ubiquitinated and degraded in the cytoplasm by the BCR(KEAP1) complex. (UniProt, Q16236)
Open in Phaseline: the race on NFE2L2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Biogen | Omaveloxolone (BIIB141) Nuclear factor erythroid 2-related factor 2 activator | NFE2L2 | Phase 3 | Friedreich Ataxia | Nov 2027 |
| Nanjing Medical University | Dimethyl Fumarate Enteric-coated Capsules Nrf2 activator and fumarate derivative; activates nuclear factor erythroid 2-related facto | NFE2L2 | Phase 3 | Type 1 Diabetes; Type 1 Diabetes Mellitus | Dec 2028 |
| NYU Langone Health | DRP-104 Glutamine antagonist | NFE2L2, KEAP1 | Phase 2 | Non Small Cell Lung Cancer | Oct 2027 |
| University Hospital, Lille | Diroximel Fumarate Nrf2 activator | NFE2L2 | Phase 2 | Stroke | May 2029 |
Friedreich Ataxia (2) Type 1 Diabetes (1) Type 1 Diabetes Mellitus (1) Stroke (1) Non Small Cell Lung Cancer (1)
small molecule (3), mixed (1)
Nanjing Medical University (1) University Hospital, Lille (1) Biogen (1) NYU Langone Health (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.